Q2 2022 report and presentation

Tromsø, Norway, 18th August 2022 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 30.4 million (21.3) and an EBITDA of NOK 9.5 million (6.0) for the second quarter of 2022. Highlights from Q2 and first 6 months 2022 ArcticZymes Technologies (AZT) had Q2 sales of NOK 30.4 million growing by 43% (Q2 2021: NOK 21.3 million) and sales for …

Welcome to the team!

We welcome Dirk Hahneiser to ArcticZymes Technologies who joins us as Vice President of Business Development and Marketing. Dirk will lead ArcticZymes Technologies´ global business development team and further develop the company´s commercial and marketing strategy. We are excited to have Dirk aboard and look forward to working with him.

ArcticZymes is attending ASGCT 25th Annual Meeting

ArcticZymes Technologies is attending the ASGCT 25th Annual Meeting in Washington, D.C. from – May 16-19. Mr. Scott Frayo is looking forward to meeting you at booth 241 for a discussion on how our SAN HQ, SAN HQ 2.0 and M-SAN HQ can improve the efficiency of your viral bioprocessing process. Our salt active nuclease (SAN) enzymes have been validated …